Skip to main content
SpringerLink
Log in

Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma

  • Original Paper
  • Published:
Urological Research Aims and scope Submit manuscript

Abstract

The M2 isoenzyme of pyruvate kinase (M2-PK) is specifically expressed in tumor cells (TuM2-PK) and has been detected in the peripheral blood of patients with renal cell carcinoma (RCC). TuM2-PK is not useful as a biological marker in localized RCC. We analysed TuM2-PK in 68 patients with metastatic RCC after initial surgery and prior to or during chemoimmunotherapy of metastases. In 50 patients, the levels of TuM2-PK were measured during chemoimmunotherapy with interleukin-2, interferon-α2a and 5-fluorouracil for up to 8 months and were correlated to response as assessed by radiological imaging techniques. TuM2-PK was quantified with a commercially available enzyme linked immunosorbent assay kit using a cut off of 15 kU/l. In 48 of 68 patients (71%), TuM2-PK was elevated above the cut-off. TuM2-PK was significantly higher in G3 tumors than in G2 tumors. In 34 of 50 patients (68%) undergoing chemoimmunotherapy, a positive correlation between TuM2-PK values and response to treatment was observed. Based on these data, we would not recommend the routine clinical use of TuM2-PK in metastatic RCC at this point.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3

Similar content being viewed by others

References

  1. Brink U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G (1994) L- and M2- pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 424: 177

    PubMed  Google Scholar 

  2. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G (1997) Quantification of tumor type M2 pyruvate kinase (TUM2-PK) in human carcinomas. Anticancer Res 17: 3153

    CAS  PubMed  Google Scholar 

  3. Figlin RA (1999) Renal cell carcinoma: management of advanced disease. J Urol 161: 381

    CAS  PubMed  Google Scholar 

  4. Fischer G, Holzrichter S, Reinacher M, Heinrichs M, Dembowski J, Eigenbrodt E (1989) Immunohistochemical demonstration of L- and M2-pyruvate kinase in primary renal cell carcinomas and their metastases. Verh Dtsch Ges Pathol 73: 422

    CAS  PubMed  Google Scholar 

  5. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JRJr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655

    Article  CAS  PubMed  Google Scholar 

  6. Klapdor R, Bahlo M, Fenner C (1999) Tumormarker M2-PK in the follow up of pancreatic and colorectal cancer disease. Abstract, 10th International Hamburg Symposium on Tumor Markers, Hamburg, Germany, 05—07.12.1999

  7. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K (2000) Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20: 5077

    CAS  PubMed  Google Scholar 

  8. Mazurek S, Scheefers-Borchel U, Scheefers H, Michel A, Basenau D, Fischer G, Dahlmann N, Laumen R, Eigenbrodt E (1993) Die Bedeutung der Pyruvatkinase in der Onkologie. notabene medici 3: 97

    Google Scholar 

  9. Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966

    PubMed  Google Scholar 

  10. Oremek GM, Eigenbrodt E, Rädle J, Zeuzem ST, Seiffert UB (1997) Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 17: 3031

    CAS  PubMed  Google Scholar 

  11. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel K-H (1999) The pyruvate kinase isoenzyme tumor M2 (TUM2-PK) as a tumor marker for renal cell carcinoma. Anticancer Res 19: 2599

    CAS  PubMed  Google Scholar 

  12. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA (2001) Tumor M2-pyruvate kinase (TUM2-PK) in plasma of patients with urological tumors. Tum Biol 22: 282

    Article  CAS  Google Scholar 

  13. Steinberg P, Storkel S, Oesch F, Thoenes W (1992) Carbohydrate metabolism in human renal clear cell carcinomas. Lab Invest 67: 506

    CAS  PubMed  Google Scholar 

  14. Wechsel HW, Petri E, Bichler KH, Feil G (1999) Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (TUM2-PK). Anticancer Res 19: 2583

    CAS  PubMed  Google Scholar 

  15. Wechsel HW, Petri E, Feil G, Nelde H, Bichler K (1999) Renal cell carcinoma. Immunohistological study to the expression of the inactive form of the pyruvate kinase. Urologe A 38: 583

    Article  CAS  PubMed  Google Scholar 

  16. Varga Z, Hegele A, Stief T, Heidenreich, Hofmann R (2002) Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker. Urol Res 30: 122

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital Charité, Humboldt University of Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany

    J. Roigas, S. Deger, J. Schroeder, A. Wille, I. Turk, K. Jung, D. Schnorr & S. A. Loening

  2. Institute of Pathobiochemistry and Laboratory Medicine, University Hospital Charité, Humboldt University of Berlin, 10117 Berlin, Germany

    B. Brux

Authors
  1. J. Roigas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Deger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Wille
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Turk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Brux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Schnorr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. A. Loening
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roigas, J., Deger, S., Schroeder, J. et al. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 31, 358–362 (2003). https://doi.org/10.1007/s00240-003-0331-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00240-003-0331-4

Keywords

Search

Navigation